<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03766334</url>
  </required_header>
  <id_info>
    <org_study_id>TJ-T1DM-CGM-001</org_study_id>
    <nct_id>NCT03766334</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Highland Barley Diet on Glucose Variability in Patients With Type 1 Diabetes Mellitus</brief_title>
  <official_title>Efficacy and Safety of Highland Barley Diet on Glucose Variability in Patients With Type 1 Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Huazhong University of Science and Technology</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Huazhong University of Science and Technology</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Approximately 80 patients will be enrolled in the study from China and randomized in a 1:1&#xD;
      ratio to one of the 2 treatment arms:diabetes diet+highland barley diet; or diabetes diet.&#xD;
&#xD;
      Study treatment will continue for 12 weeks. The primary efficacy measure is the change in&#xD;
      MAGE from continuous glucose monitoring system at 12 weeks. The study consists of 3 periods:&#xD;
      a 1-week screening (period A), a 8-day run-in period (period B) and a 12-week treatment&#xD;
      period (period C). Continuous glucose monitoring system will be used in baseline and&#xD;
      endpoint.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective, randomized, open-label comparison of the effects and safety of barley&#xD;
      meal plus diabetes diet on blood glucose fluctuations in patients with type 1 diabetes (T1DM)&#xD;
      using multiple daily insulin injections (MDI). , parallel test. About 80 patients with T1DM&#xD;
      were enrolled in the preliminary trial. During the lead-in period, no interventions were&#xD;
      given to the patient's diet from day 1 to day 4, and diabetes diet education and guidance&#xD;
      were given from day 5 to day 8, depending on the patient's blood glucose and diet.&#xD;
      Personalization of habits, weights, and activities, etc., establish a diabetes diet. At the&#xD;
      end of the lead-in period, patients were randomly divided into two treatment groups according&#xD;
      to the ratio of 1:1: Observation group: Diabetes diet + barley diet. (The barley meal group&#xD;
      diet was formulated according to the diabetes diet, but each meal was replaced with 20g&#xD;
      barley nutrition powder and other calories instead of part of the diet. In the control group:&#xD;
      Diabetes diet; dietary treatment after randomization will continue for 12 weeks. From the&#xD;
      induction period to the treatment period 6 days, treatment period 10-12 weeks&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 5, 2018</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">October 31, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Average blood glucose fluctuations at endpoint and baseline</measure>
    <time_frame>from baseline to 12-week endpoint</time_frame>
    <description>Objective to investigate the effect of combination diabetes diet and highland barley diet on glucose variability in insufficient control patients with type 1 diabetes.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Glycated hemoglobin(endpoint)-Glycated hemoglobin(baseline)</measure>
    <time_frame>from baseline to 12-week endpoint</time_frame>
    <description>Objective to investigate the effect of combination diabetes diet and highland barley diet on glucose control in patients with type 1 diabetes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>insulin dose(endpoint)-insulin dose(baseline)</measure>
    <time_frame>from baseline to 12-week endpoint</time_frame>
    <description>Objective to investigate the effect of combination diabetes diet and highland barley diet on insulin dose in patients with type 1 diabetes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life assessment scale SF-36(endpoint)-Quality of life assessment scale SF-36(baseline)</measure>
    <time_frame>from baseline to 12-week endpoint</time_frame>
    <description>Objective to investigate the effect of combination diabetes diet and highland barley diet on life quality in patients with type 1 diabetes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body mass index(endpoint)-Body mass index(baseline)</measure>
    <time_frame>from baseline to 12-week endpoint</time_frame>
    <description>Objective to investigate the effect of combination diabetes diet and highland barley diet on BMI in patients with type 1 diabetes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>beta-cell function at endpoint and baseline</measure>
    <time_frame>from baseline to 12-week endpoint</time_frame>
    <description>Objective to investigate the effect of combination diabetes diet and highland barley diet on beta-cell function in patients with type 1 diabetes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Waist circumference(endpoint)-Waist circumference(baseline)</measure>
    <time_frame>from baseline to 12-week endpoint</time_frame>
    <description>Objective to investigate the effect of combination diabetes diet and highland barley diet on waist circumference in patients with type 1 diabetes.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Type1 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Diabetes Diet+Highland Barley Diet</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Diabetes Diet+Highland Barley Diet(20g, thrice-daily)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Diabetes Diet</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>only Diabetes Diet</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Highland Barley Diet</intervention_name>
    <description>Highland Barley Diet(20g, thrice-daily)</description>
    <arm_group_label>Diabetes Diet+Highland Barley Diet</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. type 1 diabetes patients with disease duration more than one year&#xD;
&#xD;
          2. HbA1c ≥7.0 % and &lt; 11.0 %&#xD;
&#xD;
          3. Men and women (non-pregnant and using a medically approved birthcontrol method) aged ≥&#xD;
             18 and ≤ 65 years&#xD;
&#xD;
          4. BMI ≥ 18 and ≤ 26 kg/m2&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Type 2 diabetes or other specific types of diabetes&#xD;
&#xD;
          2. Pregnancy, preparation for pregnancy, lactation and women of childbearing age&#xD;
             incapable of effective contraception methods&#xD;
&#xD;
          3. Uncooperative subject because of various reasons&#xD;
&#xD;
          4. Abnormal liver function, glutamic-pyruvic transaminase (ALT) and glutamic-oxaloacetic&#xD;
             transaminase (AST) &gt; twice the upper limits of normal&#xD;
&#xD;
          5. Impairment of renal function, serum creatinine: ≥ 133mmol/L for female，≥ 135mmol/L for&#xD;
             male&#xD;
&#xD;
          6. Serious chronic gastrointestinal diseases&#xD;
&#xD;
          7. Edema&#xD;
&#xD;
          8. Serious heart diseases, such as cardiac insufficiency (level III or more according to&#xD;
             NYHA), acute coronary syndrome and old myocardial infraction&#xD;
&#xD;
          9. Blood pressure: Systolic blood pressure (SBP) ≥ 180mmHg and/or diastolic blood&#xD;
             pressure (DBP) ≥ 110mmHg&#xD;
&#xD;
         10. White blood count (WBC) &lt; 4.0×109/L or platelet count (PLT) &lt; 90×109/L，or definite&#xD;
             anemia (Hb：&lt; 120g/L for male, &lt; 110g/L for female), or other hematological diseases&#xD;
&#xD;
         11. Endocrine system diseases, such as hyperthyroidism and hypercortisolism&#xD;
&#xD;
         12. Experimental drug allergy or frequent hypoglycemia&#xD;
&#xD;
         13. Psychiatric disorders, drug or other substance abuse&#xD;
&#xD;
         14. Diabetic ketoacidosis and hyperosmolar nonketotic coma requiring insulin therapy&#xD;
&#xD;
         15. Stressful situations such as surgery, serious trauma and so on&#xD;
&#xD;
         16. Chronic hypoxic diseases such as pulmonary emphysema and pulmonary heart disease&#xD;
&#xD;
         17. Combined use of drugs effecting glucose metabolism such as glucocorticoid Tumor,&#xD;
             especially bladder tumor and/or family history of bladder tumor and/or long-term&#xD;
             hematuria&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>xuefeng Yu</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tongji Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xuefeng Yu, doctor</last_name>
    <phone>+86-13986070673</phone>
    <email>xfyu188@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>LI Liu</last_name>
    <phone>+86-18202755862</phone>
    <email>287715963@qq.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Tongji Hospital, Tongji Medical College, Huazhong University of Science and technology</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xi Chen, doctor</last_name>
      <phone>86+13667217301</phone>
      <email>amazingamycx@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>July 2, 2018</study_first_submitted>
  <study_first_submitted_qc>December 4, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">December 6, 2018</study_first_posted>
  <last_update_submitted>August 30, 2021</last_update_submitted>
  <last_update_submitted_qc>August 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Huazhong University of Science and Technology</investigator_affiliation>
    <investigator_full_name>Xuefeng Yu</investigator_full_name>
    <investigator_title>Chief of Department of Endocrinology</investigator_title>
  </responsible_party>
  <keyword>Highland Barley Diet</keyword>
  <keyword>Glucose variability</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

